Clinical trials

Filters
Clear filters
1,718 trials
TrialSponsorPhaseStatusPrimary completion
A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early ADNCT06709014ANVSPhase 3Active not recruiting2027-12Estimated
A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian CancerNCT06710288IBRXPhase 2Recruiting2027-05Estimated
A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy InfantsNCT06720038PCVXPhase 2Active not recruiting2027-12Estimated
Efficacy Study of EVO301 in Moderate to Severe Atopic DermatitisNCT06723405EVMNPhase 2Completed2025-11-17Actual
Efficacy and Safety of VDPHL01 in Males With AGANCT06724614MANEPhase 2, Phase 3Active not recruiting2026-02Estimated
A Study of Barzolvolimab in Patients With Atopic DermatitisNCT06727552Celldex TherapeuticsPhase 2Active not recruiting2026-05-06Actual
A Study of Lorigerlimab in Participants With Advanced Solid TumorsNCT06730347MacroGenicsPhase 2Recruiting2027-07Estimated
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsNCT06736262JSPRPhase 2Terminated2026-07-21Actual
An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension StudyNCT06736509AXSMPhase 3Terminated2025-02-17Actual
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection FractionNCT06736574CytokineticsPhase 3Recruiting2027-09Estimated
A Phase 3 Trial of DT120 for Generalized Anxiety Disorder (Voyage)NCT06741228Definium Therapeutics US, Inc.Phase 3Active not recruiting2026-07-15Actual
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor TherapyNCT06745908IBRXPhase 3Recruiting2028-09Estimated
Avexitide for Treatment of Post-Bariatric HypoglycemiaNCT06747468AMLXPhase 3Active not recruiting2026-07-08Actual
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic FibrosisNCT06747858Arcturus Therapeutics, Inc.Phase 2Recruiting2027-06Estimated
A Study of NE3107 in Early Parkinson'sNCT06757010BIVIPhase 2Completed2026-05-01Actual
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)NCT06757634CELCPhase 3Recruiting2029-03-31Estimated
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546RYTMPhase 3Recruiting2027-03-13Estimated
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514Summit TherapeuticsPhase 3Recruiting2028-04Estimated
A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic HypersomniaNCT06767683Alkermes, Inc.Phase 2, Phase 3Recruiting2030-06Estimated
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)NCT06768671MoonLake Immunotherapeutics AGPhase 3Completed2026-09-28Actual
A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597RYTMPhase 2Active not recruiting2026-11-03Actual
A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial CancerNCT06774131URGNPhase 3Recruiting2027-03Estimated
This is a Study Evaluating the Efficacy and Safety of LTG-001 for Acute Pain After Surgical Removal of Impacted Third MolarsNCT06774625Latigo BiotherapeuticsPhase 2Completed2025-08-08Actual
A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379XENEPhase 3Terminated2026-10-28Actual
Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain MetastasesNCT06777433RADXPhase 2Active not recruiting2026-04-23Actual
A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and HypertensionNCT06785454MLYSPhase 2Completed2025-12-17Actual
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AMLNCT06788756MBRXPhase 2, Phase 3Recruiting2029-08Estimated
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCNCT06788990Bicara TherapeuticsPhase 2, Phase 3Recruiting2028-04Estimated
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)NCT06789913RLAYPhase 2Recruiting2031-07Estimated
Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaNCT06790966PDSBPhase 3Terminated2026-08-25Actual

Primary completion marks the end of data collection for the main study measures, not a results publication date.